All In Biotech

Drug Trial Radar · NCT04707768

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

456

Actual

Start

Jun 18, 2021

Primary completion

Jan 6, 2023

Study completion Jan 30, 2023

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.

Conditions

  • Anemia Associated With Chronic Kidney Disease (CKD)

Interventions

  • VadadustatDrug

    oral tablets

  • Mircera®Drug

    intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)Time frame: Baseline; Weeks 20 to 26

Locations

58 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Pine Bluff, Arkansas

  • Research Site

    El Centro, California

  • Research Site

    Escondido, California

  • Research Site

    Fresno, California

  • Research Site

    Granada Hills, California

  • Research Site

    Porterville, California

  • Research Site

    San Diego, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Hockessin, Delaware

  • Research Site

    Bradenton, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site#1

    Coral Springs, Florida

  • Research Site#2

    Coral Springs, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Buford, Georgia

  • Research Site

    Dalton, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Nampa, Idaho

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Plymouth, Massachusetts

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Rochester Hills, Michigan

  • Research Site

    Saint Clair Shores, Michigan

  • Research Site

    Brookhaven, Mississippi

  • Research Site

    Columbus, Mississippi

  • Research Site

    Tupelo, Mississippi

  • Research Site

    North Platte, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Reno, Nevada

  • Research Site

    Portsmouth, New Hampshire

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Gallup, New Mexico

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.